Please refer to Performance Reports and Financial Highlights .

Please refer to materials posted under Financial Reports .

Please refer to the Financial Reports and Corporate Reports posted under IR Library .

Our contact details can be found here .

Announcement of financial results is made each May. For details, please refer to IR Calendar .

Please refer to News for the latest information.

“TYO:4528” for the Tokyo Stock Exchange.

100 shares.

A The dates of right allotment (record dates) for dividends are September 30 and March 31 for interim and year-end dividends, respectively. (To receive dividends, a shareholder must be recorded in the shareholder register current on the date of right allotment (record date). The effective date of the distribution of year-end dividends is typically in June. The effective date of the distribution of interim dividends is typically in early December.

Generally, the meeting is held in June each year. Please refer to IR Calendar .

Please refer to Shareholder Return Policy - Dividends Distribution (Past ten years).

Please refer to Financial Reports .

We do not offer any shareholder benefits.

Based on our Sustainable Management Policy, we strive to realize a sustainable society. For details, please refer to Ono’s Approach to Sustainability .

Based on our Medium- to Long-term Environmental Vision, “Environment Challenging Ono Vision (ECO VISION 2050),” we are striving for the resolution of global environmental issues. For details, please refer to our Environment page.

Our business activities are based on a growth strategy formulated for the realization of our Corporate Philosophy and our aim of being a Global Specialty Pharma. Human resources support implementation of these strategies and the sustainable growth of our business. We therefore strive to develop human capital, considering it one of our important management issues. For details, please refer to Expansion of Human Capital (Talent Development and Employment) .

We adopt the viewpoint of patients, undertaking safety and quality assurance activities throughout the lifecycle of pharmaceutical products from a global perspective. We constantly check to ensure the quality of pharmaceutical products, and incorporate feedback from medical professionals and patients into further quality enhancement. For details, please refer to Safety and Quality Assurance .

We respect the lives of animals, and believe that animal experimentation must be conducted from the perspective of animal welfare, endeavoring to cause the minimum suffering possible, with the minimum number of animals required to achieve our aims. Research using animal experimentation is conducted with consideration of the 3Rs*, and we obtain certification from a third-party organization.
For details, please refer to Research and Development Ethics
*3Rs
Replacement: methods that utilize alternative methods for non-animal experiments
Reduction: methods that minimize the number of animals used
Refinement: methods that avoid unnecessary distress to animals

We abide by all laws and ordinances and consider the strengthening of corporate governance as an important issue in efforts to boost corporate value to gain the trust of all stakeholders. For details, please refer to Corporate Governance .

We formulated Ono’s Social Contribution Activities Global Policy aimed at contributing to the development of a sustainable society. We undertake various social contribution activities with consideration of their relationship to our current and future business activities, as well as our management resources. For details, please refer to Social Contribution Activities .